Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | LVTX |
---|---|---|
10:03 ET | 1900 | 1.68 |
10:08 ET | 500 | 1.6603 |
10:17 ET | 350 | 1.65 |
10:21 ET | 975 | 1.7 |
11:40 ET | 100 | 1.7 |
12:20 ET | 100 | 1.7 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
LAVA Therapeutics NV | 43.9M | -1.9x | --- |
Cue Biopharma Inc | 43.3M | -0.7x | --- |
Atara Biotherapeutics Inc | 43.2M | -0.2x | --- |
DURECT Corp | 42.2M | -2.5x | --- |
Kezar Life Sciences Inc | 57.7M | -0.6x | --- |
BioLine RX Ltd | 48.7M | -0.7x | --- |
LAVA Therapeutics NV, formerly known as Lava Therapeutics BV, is a provider of biotechnology research and development services based in the Netherlands. The Company focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $43.9M |
---|---|
Revenue (TTM) | $7.4M |
Shares Outstanding | 26.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.50 |
EPS | $-0.90 |
Book Value | $1.95 |
P/E Ratio | -1.9x |
Price/Sales (TTM) | 5.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -371.48% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.